On March 5, 2024, QuidelOrtho issued a correction notification to affected consignees. QuidelOrtho asked consignees to take the following actions:
1. Please complete and return the attached confirmation of notification form to QuidelOrtho via fax
at 858.203.9297 or email at
[email protected].
2. Indicate the amount of product to be replaced on the confirmation of notification form. You are
not required to take any action related to already used kit material.
3. If requesting replacement product, discontinue use, render unusable, and discard the
remaining inventory of affected lot numbers once replacement product arrives.
4. If unaffected replacement product is not immediately available or you wish to continue testing,
please follow these steps, as applicable, to minimize patient risk:
4a. Immediately prior to running a test, carefully inspect each unused InflammaDry test
device to ensure two faint orange lines appear in the result window prior to
use. Only open and inspect the test device immediately prior to use as the device should not be stored outside of the foil pouch.
4b. Do not use any of the InflammaDry test devices if two faint orange lines are not visible prior to use. Please request replacement for any unused devices using the confirmation of notification form.
.
4c. Perform external controls with each new lot, each new shipment, and every 30 days, per the package insert recommendations. Ensure the positive control produces expected results.
5. To report adverse events, contact your local Technical Solutions Center. Adverse reactions or quality problems experienced with the use of this product may also be reported to the FDA s MedWatch Adverse Event Reporting program: www.fda.gov/medwatch/report.htm, 1-800-332-1088.